As a rich source of novel and bioactive compounds, marine fungi continue to be of major research interest [1] . Sea cucumbers host a rich diversity and abundance of fungi [2a] , which have produced many novel and bioactive secondary metabolites, such as diterpene glycosides from Acremonium sp.
[2b], a benzofuran from Alternaria sp., an isopimarane diterpene from Epicoccum sp. [3] , an acid anhydride from Fusarium sp., and polyhydroxy cyclohexanols and 12-membered macrolides from Dendrodochium sp. [4, 5] . During a study of the bioactive metabolites from fungi associated with sea cucumbers collected around Zhifu Island, Yantai City, China, the ethyl acetate extract of Aspergillus terreus (HS-Y-1) showed antiangiogenesis activity, producing 40% inhibition at 100 μg/mL. From this fungus, three compounds (Figure 1 ), (+)-butyrolactone IV (1), butyrolactone I (2) and terrelactone A (3) were obtained; both 1 and 2 showed strong antiangiogenesis activity.
Compound 1 was isolated as pale yellow glue producing an [M+H] + ion in its HRTOFMS at m/z 441.4290. Its UV spectrum showed absorption at 223 and 310 nm. Its NMR spectral data were consistent with (+)-butyrolactone IV [6] . Compound 2, a pale yellow solid, displayed an [M+H] + ion at m/z 425.1570 in its HRTOFMS, consistent with a molecular formula of C 24 H 24 O 7 . Its UV spectrum showed absorption at 223 and 309 nm. These, along with 1 H and 13 C NMR spectroscopic data, identified compound 2 as butyrolactone I [7] . The HRTOFMS of compound 3, obtained as pale oil, exhibited an [M+Na] + ion at 465.1519, which was consistent with C 24 H 26 O 8 . Its UV spectrum showed characteristic absorption of butyrolactones at 230 and 310 nm. Combined with 1 H and 13 C NMR spectral data, compound 3 was identified as terrelactone A [8a] . were consistent with the literature data, which confirmed the 4R-configuration [6,7,8a] .
The antiangiogenic activities of compounds 1 and 2 were evaluated using zebrafish assay, in terms of the inhibition on the growth of intersegmental vessels, with PTK787 as positive control (IC 50 0.15 μg/mL). The results showed that both 1 and 2 could significantly inhibit the growth of intersegmental vessels of embryos compared to the control (0.1% DMSO in sterile salt water). The inhibition ratio of compound 1 was 43.4% at a concentration of 100 μg/mL and 2 was 28.7% at a concentration of 10 μg/mL (Table 1) .
Compound 3 has not been tested its antiangiogenesis activity for little amount. 
also showed mixed-type inhibitory activity against yeast α-glucosidase, antioxidant activity [8c], anti-H1N1 activity [8a] , as well as inhibitory activities against eukaryotic cyclin-dependent kinase (CDK), preventing apoptosis [6] . There is no previous report available on the antiangiogenesis activity of butyrolactones. Angiogenesis inhibitors have been successfully used for cancer therapy in the clinic, and increasing attention has been paid to the development of marine-derived angiogenesis inhibitors [9] . 
Experimental

General
Identification of the endophytic isolate:
The fungus was grown on PDA for 5 days at 28°C. Genomic DNA was extracted and purified using the Fungal DNA Kit 50 (OMEGA, USA), according to the manufacturer's instructions, suitably modified. For identification and differentiation, the Internal Transcript Spacer regions (ITS4 and ITS5) and the intervening 5.8S rRNA region were amplified and sequenced. The ITS regions of the fungus were amplified by PCR with the universal ITS primers, ITS5 (5'-GGA AGT AAA AGT CGT AAC AAG G-3') and ITS4 (5'-TCC TCC GCT TAT TGA TAT GC-3'). The PCR products were then purified and desalted using the EZ Spin column PCR product purification kit (BBI) and sequenced. The sequencing results were aligned with the nucleotide-nucleotide database (BLASTn) of the U.S. National Center for Biotechnology Information (NCBI) for final identification of fungi.
Fermentation, extraction, and isolation:
The fungal strain was cultivated in solid medium at 28°C for 28 days in 40 x 500 mL Erlenmeyer flasks, each containing 80 g rice in 120 mL of seawater. The combined cultures were extracted 3 times by shaking with an equal volume of ethyl acetate; the combined extracts were then concentrated below 50 °C to obtain the crude dry extract. This was subjected to silica gel CC, eluting with a gradient of light petroleum to ethyl acetate. Fractions (Fr. 5-8) of 30 mL were collected and combined by TLC examination. Fractions containing the desired compounds were further purified by Sephadex LH-20 chromatography, eluting with mixtures of light petroleum-CHCl 3 Antiangiogenesis assay: Fertilized eggs were treated with pronase to remove chorions, and raised in embryo medium (60 mmol/L NaCl, 2.4 mmol/L sodium bicarbonate, 0.8 mmol/L CaCl 2 , 0.67 mmol/L KCl, and 10 mmol/L HEPES). Embryos were arrayed into 24-well plates (8 embryos per well) in 2 mL of embryo medium for 1 day postfertilization. Stock solutions (10 mg/mL) of all samples were prepared by dissolving the test compounds in 100% DMSO. These stock solutions were diluted in embryo medium to obtain working solutions with the test compounds dissolved in 0.1% DMSO. These working solutions were aliquoted into 24-well plates. After 24 h of treatment, the intersegmental vessels (ISV) of embryos were visualized by green fluorescent protein labeling under a fluorescent microscope. A fluorescent image of each embryo was captured using the DP72 imaging system. The length of the ISV on the captured image was measured by Image Pro Plus software. The antiangiogenesis activities of compounds were calculated from the inhibition ratio of angiogenesis. The positive control for this assay was 0.2 μg/mL PTK787, a VEGFR antagonist, and the negative control was 0.1% DMSO.
